Lapatinib: a sword with two edges.

Pathology Oncology Research : POR
László Kopper

Abstract

Lapatinib is an oral dual tyrosine kinase inhibitor targeting EGFR1 and EGFR2 (HER2). Phase I trials have shown that lapatinib is well tolerated, with mild diarrhea and skin rush as common adverse effects, and low cardiotoxicity. Phase II and III trials provided evidences on clinical effectiveness in advanced or metastatic breast cancer and potential against brain metastases. Lapatinib is active in combination with trastuzumab and in trastuzumab-resistant patients, moreover it has synergistic action with capecitabine. Several clinical trials are in progress to explore the effectiveness of lapatinib in other combinations and against several tumor types.

References

Feb 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles L VogelMichael Press
May 2, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Aditya BardiaMatthew P Goetz
May 10, 2006·Proceedings of the National Academy of Sciences of the United States of America·Wenle XiaNeil L Spector
Dec 29, 2006·The New England Journal of Medicine·Charles E GeyerDavid Cameron
Mar 8, 2007·Journal of the National Cancer Institute·Rabiya S Tuma
Jun 5, 2007·The International Journal of Biochemistry & Cell Biology·Christian WidakowichMartine Piccart-Gebhart
Sep 27, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D BilanciaL Manzione
Jul 20, 2007·Nature Reviews. Drug Discovery·Beverly MoyPaul Goss
Aug 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Wandena S Siegel-LakhaiJan H M Schellens
Aug 21, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Quincy S C ChuEric K Rowinsky
Sep 11, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul M HarariJames A Bonner
Sep 12, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R S MidgleyM R Middleton
May 21, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anna Maria StornioloHoward A Burris
Jul 23, 2008·Molecular Cancer Therapeutics·Dongwei ZhangNaoto T Ueno

❮ Previous
Next ❯

Citations

Oct 17, 2009·Journal of Biomedicine & Biotechnology·Raja Loganantharaj, Jun Chung
May 30, 2015·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Michael JuchumStefan A Laufer
Mar 27, 2012·Molecular Oncology·Joseph P Garay, Joe W Gray
Jul 28, 2016·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Joanna K TowlesKlarissa D Jackson
Feb 12, 2017·Chemical Biology & Drug Design·Hua-Li QinSyed Nasir Abbas Bukhari
Jan 1, 2010·American Journal of Clinical Oncology·Srikala S SridharMalcolm J Moore
Feb 2, 2018·Oncology Letters·Lu LiuBeizhong Liu
Mar 22, 2014·Biomedical Reports·Shu Guang Li, Li Li
Jan 1, 2018·Journal of Receptor and Signal Transduction Research·Suresh Kumar MuthuvelHemalatha K
Aug 21, 2020·Archives of Toxicology·Guillermo García-LainezInmaculada Andreu
Feb 6, 2019·Oncogene·Mengxiong WangBrian K Law

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Related Papers

Recent Patents on Anti-cancer Drug Discovery
Oluwakemi Obajimi
The Annals of Pharmacotherapy
Michael H Nelson, Christian R Dolder
Expert Opinion on Biological Therapy
Filippo MontemurroMassimo Aglietta
© 2022 Meta ULC. All rights reserved